Document and Entity Information
Document and Entity Information - shares | 6 Months Ended | |
Jun. 30, 2019 | Jul. 24, 2019 | |
Document And Entity Information | ||
Entity Registrant Name | BIOSCIENCE NEUTRACEUTICALS, INC. | |
Entity Central Index Key | 0001555995 | |
Document Type | 10-Q | |
Amendment Flag | false | |
Current Fiscal Year End Date | --12-31 | |
Entity Small Business | true | |
Entity Emerging Growth Company | false | |
Entity Current Reporting Status | Yes | |
Document Period End Date | Jun. 30, 2019 | |
Entity Filer Category | Non-accelerated Filer | |
Document Fiscal Period Focus | Q2 | |
Document Fiscal Year Focus | 2019 | |
Entity Shell Company | false | |
Entity Common Stock Shares Outstanding | 8,042,516 |
BALANCE SHEETS
BALANCE SHEETS - USD ($) | Jun. 30, 2019 | Dec. 31, 2018 |
Current Assets | ||
Prepaid expense | $ 6,000 | |
Total Current Assets | 6,000 | |
Total Assets | 6,000 | |
Current Liabilities | ||
Accounts payable and accrued liabilities | 1,550 | 7,066 |
Accrued interest | 41,149 | 29,747 |
Due to related parties | 128,785 | 100,172 |
Convertible notes | 14,878 | 22,878 |
Notes payable | 27,500 | 27,500 |
Total Current Liabilities | 213,862 | 187,363 |
Long-term note payable | 3,957 | 3,957 |
Total Liabilities | 217,819 | 191,320 |
STOCKHOLDERS' DEFICIT | ||
Preferred Stock, par value $0.0001, 50,000,000 shares authorized, 0 shares issued and outstanding, respectively | ||
Common Stock, par value $0.0001, 100,000,000 shares authorized, 8,042,516 and 242,516 shares issued and outstanding, respectively | 804 | 24 |
Additional paid-in capital | 562,055 | 132,923 |
Accumulated deficit | (780,678) | (318,267) |
Total Stockholders' Deficit | (217,819) | (185,320) |
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT | $ 6,000 |
BALANCE SHEETS (Parenthetical)
BALANCE SHEETS (Parenthetical) - $ / shares | Jun. 30, 2019 | Dec. 31, 2018 |
STOCKHOLDERS' DEFICIT | ||
Preferred stock, shares par value | $ 0.0001 | $ 0.0001 |
Preferred stock, shares authorized | 50,000,000 | 50,000,000 |
Preferred stock, shares issued | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 |
Common stock, shares par value | $ 0.0001 | $ 0.0001 |
Common stock, shares authorized | 100,000,000 | 100,000,000 |
Common stock, shares issued | 8,042,516 | 242,516 |
Common stock, shares outstanding | 8,042,516 | 242,516 |
STATEMENTS OF OPERATIONS
STATEMENTS OF OPERATIONS - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2019 | Jun. 30, 2018 | Jun. 30, 2019 | Jun. 30, 2018 | |
STATEMENTS OF OPERATIONS | ||||
Revenue | ||||
Operating Expenses | ||||
General and administration | 382 | |||
Professional | 10,090 | 18,519 | 28,715 | 20,007 |
Stock based compensation | 421,912 | |||
Total operating expenses | 10,090 | 18,519 | 451,009 | 20,007 |
Net loss from operations | (10,090) | (18,519) | (451,009) | (20,007) |
Other expense | ||||
Interest expense | (5,224) | (6,363) | (11,402) | (12,095) |
Total other expense | (5,224) | (6,363) | (11,402) | (12,095) |
Net loss before taxes | (15,314) | (24,882) | (462,411) | (32,102) |
Provision for income taxes | ||||
Loss from Continuing Operations | (15,314) | (24,882) | (462,411) | (32,102) |
Discontinued operations | ||||
Loss from discontinued operations | (1,736) | (6,648) | ||
Loss from Discontinued Operations, Net of Tax Benefits | (1,736) | (6,648) | ||
Net loss | $ (15,314) | $ (26,618) | $ (462,411) | $ (38,750) |
Net Loss Per Common Share - Basic and Diluted | $ 0 | $ 0 | $ (0.10) | $ (0.16) |
Weighted Average Common Shares Outstanding | 8,042,516 | 9,680,435 | 4,648,011 | 242,500 |
STATEMENTS OF STOCKHOLDERS' EQU
STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) | Total | Preferred Stock Shares | Common stock Shares | Additional Paid-in Capital | Accumulated Deficit |
Balance, shares at Dec. 31, 2017 | 9,700,000 | ||||
Balance, Amount at Dec. 31, 2017 | $ (129,544) | $ 970 | $ 114,215 | $ (244,729) | |
Net loss for the period | (12,132) | (12,132) | |||
Balance, shares at Mar. 31, 2018 | 9,700,000 | ||||
Balance, amount at Mar. 31, 2018 | (141,676) | $ 970 | 114,215 | (256,861) | |
Balance, shares at Dec. 31, 2017 | 9,700,000 | ||||
Balance, Amount at Dec. 31, 2017 | (129,544) | $ 970 | 114,215 | (244,729) | |
Net loss for the period | (38,750) | ||||
Balance, shares at Jun. 30, 2018 | 9,700,000 | ||||
Balance, amount at Jun. 30, 2018 | (168,294) | $ 970 | 114,215 | (283,479) | |
Balance, shares at Mar. 31, 2018 | 9,700,000 | ||||
Balance, Amount at Mar. 31, 2018 | (141,676) | $ 970 | 114,215 | (256,861) | |
Net loss for the period | (26,618) | (26,618) | |||
Balance, shares at Jun. 30, 2018 | 9,700,000 | ||||
Balance, amount at Jun. 30, 2018 | (168,294) | $ 970 | 114,215 | (283,479) | |
Balance, shares at Dec. 31, 2018 | 242,516 | ||||
Balance, Amount at Dec. 31, 2018 | (185,320) | $ 24 | 132,923 | (318,267) | |
Common stock issued for service, shares | 7,000,000 | ||||
Common stock issued for service, amount | 421,912 | $ 700 | 421,212 | ||
Common stock issued for conversion of debt, shares | 800,000 | ||||
Common stock issued for conversion of debt, amount | 8,000 | $ 80 | 7,920 | ||
Net loss for the period | (462,411) | (447,097) | |||
Balance, shares at Jun. 30, 2019 | 8,042,516 | ||||
Balance, amount at Jun. 30, 2019 | (217,819) | $ 804 | 562,055 | (780,678) | |
Balance, shares at Mar. 31, 2019 | 8,042,516 | ||||
Balance, Amount at Mar. 31, 2019 | (202,505) | $ 804 | 562,055 | (765,364) | |
Net loss for the period | (15,314) | (15,314) | |||
Balance, shares at Jun. 30, 2019 | 8,042,516 | ||||
Balance, amount at Jun. 30, 2019 | $ (217,819) | $ 804 | $ 562,055 | $ (780,678) |
STATEMENTS OF CASH FLOWS
STATEMENTS OF CASH FLOWS - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2019 | Jun. 30, 2018 | Jun. 30, 2019 | Jun. 30, 2018 | |
Cash Flows from Operating Activities | ||||
Net loss from Continued Operations | $ (15,314) | $ (24,882) | $ (462,411) | $ (32,102) |
Net loss from Discontinued Operations | (1,736) | (6,648) | ||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||
Stock based compensation | 421,912 | |||
Changes in operating assets and liabilities: | ||||
Inventory | (1,715) | |||
Prepaid expense | 6,000 | |||
Accounts payable and accrued liabilities | (5,516) | (2,000) | ||
Accrued interest | 11,402 | 12,095 | ||
Net Cash Used in Operating Activities | (28,613) | (30,370) | ||
Cash Flows from Financing Activities: | ||||
Loan from related parties | 28,613 | 28,669 | ||
Proceeds from notes payable | 3,957 | |||
Net Cash Provided by Financing Activities | 28,613 | 32,626 | ||
Net Change in Cash and Cash Equivalents | 2,256 | |||
Cash and Cash Equivalents, beginning of period | 1,488 | |||
Cash and Cash Equivalents, end of period | $ 3,744 | 3,744 | ||
Supplemental Disclosure Information: | ||||
Cash paid for interest | ||||
Cash paid for taxes | ||||
Non Cash Investing and Financing Activities | ||||
Common stock issued for conversion of debt | $ 8,000 |
ORGANIZATION AND DESCRIPTION OF
ORGANIZATION AND DESCRIPTION OF BUSINESS | 6 Months Ended |
Jun. 30, 2019 | |
ORGANIZATION AND DESCRIPTION OF BUSINESS | |
NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS | Organization, Nature of Business and Trade Name Bioscience Neutraceuticals, Inc. (the Company) was incorporated in the State of Nevada on June 15, 2010 under the name JobLocationMap Inc. The Company is located at 500 North Michigan Avenue #600, Chicago, Illinois. The Companys activities are subject to significant risks and uncertainties including failing to secure additional funding to operationalize the Companys future operations. The Company is currently evaluating and reviewing the future course of business. Disposal of business On October 1, 2018, the Company disposed of its previous online application business. The change of the business qualified as a discontinued operation of the Company and accordingly, the Company has excluded results of the operations from its Statements of Operations to present this business in discontinued operations. Reverse Stock Split On January 18, 2019, a majority of our shareholders approved a reverse stock split on a basis of 40 old shares for one (1) new share of our issued and outstanding common stock. The reverse split has been reviewed by the Financial Industry Regulatory Authority and has been approved for filing with an effective date of February 7, 2019. All share and per share information in these financial statements retroactively reflect this stock distribution. |
SUMMARY OF SIGNIFICANT ACCOUNTI
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | 6 Months Ended |
Jun. 30, 2019 | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | |
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | Basis of Presentation The accompanying unaudited financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions for Form 10-Q and Article 210 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. All such adjustments are of a normal recurring nature. Operating results for the six months ended June 30, 2019, are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2019. For further information, refer to the financial statements and footnotes thereto included in the Corporations filed Form 10-K for the year ended December 31, 2018. Reclassifications Certain amounts in the prior period financial statements have been reclassified to conform to the current period presentation. These reclassifications had no effect on reported net (loss). Use of Estimates The preparation of financial statements in accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. A change in managements estimates or assumptions could have a material impact on Bioscience Neutraceuticals, Inc.s financial condition and results of operations during the period in which such changes occurred. Actual results could differ from those estimates. Bioscience Neutraceuticals, Inc.s financial statements reflect all adjustments that management believes are necessary for the fair presentation of their financial condition and results of operations for the periods presented. |
GOING CONCERN
GOING CONCERN | 6 Months Ended |
Jun. 30, 2019 | |
GOING CONCERN | |
NOTE 3 - GOING CONCERN | The Companys financial statements are prepared using accounting principles generally accepted in the United States of America applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. However, the Company does not have an established source of revenues sufficient to cover its operating costs and to allow it to continue as a going concern. Under the going concern assumption, an entity is ordinarily viewed as continuing in business for the foreseeable future with neither the intention nor the necessity of liquidation, ceasing trading, or seeking protection from creditors pursuant to laws or regulations. Accordingly, assets and liabilities are recorded on the basis that the entity will be able to realize its assets and discharge its liabilities in the normal course of business. During the next year, the Companys foreseeable cash requirements will relate to continual development of the operations of its business, maintaining its good standing and making the requisite filings with the Securities and Exchange Commission, and the payment of expenses associated with research and development. The Company may experience a cash shortfall and be required to raise additional capital. Historically, it has mostly relied upon internally generated funds and funds from the sale of shares of stock to finance its operations and growth. Management may raise additional capital through future public or private offerings of the Companys stock or through loans from private investors, although there can be no assurance that it will be able to obtain such financing. The Companys failure to do so could have a material and adverse effect upon it and its shareholders. In the past year, the Company funded operations by using cash proceeds received through the issuance of common stock and loan from related party. For the coming year, the Company plans to continue to fund the Company through debt and securities sales and issuances until the company generates enough revenues through the operations as stated above. |
NOTE PAYABLE
NOTE PAYABLE | 6 Months Ended |
Jun. 30, 2019 | |
NOTE PAYABLE | |
NOTE 4 - NOTE PAYABLE | On June 9, 2017, the Company issued note payable of $7,500 to a third party. The note is a 40 % interest bearing promissory note that is payable on demand. On August 14, 2017, the Company issued note payable of $20,000 to a third party. The note is a 40 % interest bearing promissory note that is payable on demand. On March 31, 2018, the Company issued note payable of $3,957 to a third party. The note is a 57% interest bearing promissory note that is payable on March 31, 2023. As of June 30, 2019, and December 31, 2018, the Company owed notes payable of $27,500 and $27,500, Long-term note payable of $3,957 and $3,957 and accrued interest of $24,030 and $17,457, respectively. During the six months ended June 30, 2019 and 2018, the Company recognized interest expense of $6,573 and $6,017, respectively. |
CONVERTIBLE NOTE PAYABLE
CONVERTIBLE NOTE PAYABLE | 6 Months Ended |
Jun. 30, 2019 | |
CONVERTIBLE NOTE PAYABLE | |
NOTE 5 - CONVERTIBLE NOTE PAYABLE | On December 31, 2017, the Company issued a convertible note of $4,875 with a conversion price of $0.01. The convertible note is unsecured, bears interest at 57% per annum, has no maturity date and due on demand. The Company recorded a discount on the convertible note due to a beneficial conversion feature of $4,875 and amortized $4,875 for the year ended December 31, 2017. During the six months ended June 30, 2019, the convertible note of $4,000 was converted into 400,000 shares of common stock. On December 31, 2017, the Company issued a convertible note of $6,803 with a conversion price of $0.01. The convertible note is unsecured, bears interest at 57% per annum, has no maturity date and due on demand. The Company recorded a discount on the convertible note due to a beneficial conversion feature of $6,803 and amortized $6,803 for the year ended December 31, 2017. During the six months ended June 30, 2019, the convertible note of $4,000 was converted into 400,000 shares of common stock. On December 31, 2017, the Company issued a convertible note of $11,200 with a conversion price of $0.005. The convertible note is unsecured, bears interest at 50% per annum, has no maturity date and due on demand. The Company recorded a discount on the convertible note due to a beneficial conversion feature of $11,200 and amortized $11,200 for the year ended December 31, 2017. As of June 30, 2019, and December 31, 2018, the Company owed convertible notes payable of $14,878 and $22,878 and accrued interest of $17,118 and $12,290, respectively. During the six months ended June 30, 2019 and 2018, the Company recognized interest expense of $4,829 and $6,078, respectively. |
EQUITY
EQUITY | 6 Months Ended |
Jun. 30, 2019 | |
EQUITY | |
NOTE 6 - EQUITY | The Company has authorized 100,000,000 shares of common stock with a par value of $0.0001 and 50,000,000 shares of preferred stock with a par value of $0.0001. Preferred stock As of June 30, 2019, and December 31, 2018, there was no shares issued and outstanding. Common stock During the six months ended June 30, 2019, the Company issued 7,800,000 shares of common stock as follows; · 7,000,000 shares to our CEO for compensation · 800,000 shares for conversion of debts of $8,000 8,042,516 and 242,516 shares of common stock were issued and outstanding as of June 30, 2019 and December 31, 2018. |
RELATED TRANSACTIONS
RELATED TRANSACTIONS | 6 Months Ended |
Jun. 30, 2019 | |
RELATED TRANSACTIONS | |
NOTE 7 - RELATED TRANSACTIONS | Due to related parties During the six months ended June 30, 2019 and 2018, the Company received loans from the Related Party Director of $28,613 and $28,669 to pay for operating expenses, respectively. As of June 30, 2019 and December 31, 2018, related party loan payable outstanding is $128,785 and $100,172, respectively. |
DISCONTINUED OPERATIONS
DISCONTINUED OPERATIONS | 6 Months Ended |
Jun. 30, 2019 | |
DISCONTINUED OPERATIONS | |
NOTE 8 - DISCONTINUED OPERATIONS | During the year ended December 31, 2018, the Company disposed of online map application business. The change of the business qualified as a discontinued operation of the Company and accordingly, the Company has excluded results of the operations from its Statements of Operations to present this business in discontinued operations. The following table shows the results of operations which are included in the loss from discontinued operations: Three Months Ended Six Months Ended June 30, June 30, 2019 2018 2019 2018 Revenue $ - 2,183 $ - 4,470 Cost of goods - (1,644 ) - (6,398 ) Gross profit - 539 - (1,928 ) General and administration - 2,275 - 4,470 Professional - - - 250 Operating loss - (1,736 ) - (6,648 ) Income tax provision - - - - Loss from discontinued operations, net of tax - (1,736 ) - (6,648 ) |
SUBSEQUENT EVENT
SUBSEQUENT EVENT | 6 Months Ended |
Jun. 30, 2019 | |
SUBSEQUENT EVENT | |
NOTE 9 - SUBSEQUENT EVENT | Management has evaluated potential subsequent events through the date the financial statements were issued. Based on our evaluation no events have occurred that require disclosure. |
SUMMARY OF SIGNIFICANT ACCOUN_2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) | 6 Months Ended |
Jun. 30, 2019 | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) | |
Basis of Presentation | The accompanying unaudited financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions for Form 10-Q and Article 210 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. All such adjustments are of a normal recurring nature. Operating results for the six months ended June 30, 2019, are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2019. For further information, refer to the financial statements and footnotes thereto included in the Corporations filed Form 10-K for the year ended December 31, 2018. |
Reclassifications | Certain amounts in the prior period financial statements have been reclassified to conform to the current period presentation. These reclassifications had no effect on reported net (loss). |
Use of Estimates | The preparation of financial statements in accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. A change in managements estimates or assumptions could have a material impact on Bioscience Neutraceuticals, Inc.s financial condition and results of operations during the period in which such changes occurred. Actual results could differ from those estimates. Bioscience Neutraceuticals, Inc.s financial statements reflect all adjustments that management believes are necessary for the fair presentation of their financial condition and results of operations for the periods presented. |
DISCONTINUED OPERATIONS (Tables
DISCONTINUED OPERATIONS (Tables) | 6 Months Ended |
Jun. 30, 2019 | |
DISCONTINUED OPERATIONS (Tables) | |
Disposal groups including discontinued operations | Three Months Ended Six Months Ended June 30, June 30, 2019 2018 2019 2018 Revenue $ - 2,183 $ - 4,470 Cost of goods - (1,644 ) - (6,398 ) Gross profit - 539 - (1,928 ) General and administration - 2,275 - 4,470 Professional - - - 250 Operating loss - (1,736 ) - (6,648 ) Income tax provision - - - - Loss from discontinued operations, net of tax - (1,736 ) - (6,648 ) |
ORGANIZATION AND DESCRIPTION _2
ORGANIZATION AND DESCRIPTION OF BUSINESS (Details Narrative) | 1 Months Ended | 6 Months Ended |
Jan. 18, 2019 | Jun. 30, 2019 | |
ORGANIZATION AND DESCRIPTION OF BUSINESS (Details Narrative) | ||
State of incorporation | Nevada | |
Date of incorporation | Jun. 15, 2010 | |
Stockholders' equity, reverse stock split | 40 old shares for one |
NOTE PAYABLE (Details Narrative
NOTE PAYABLE (Details Narrative) - USD ($) | 6 Months Ended | |||||
Jun. 30, 2019 | Jun. 30, 2018 | Dec. 31, 2018 | Mar. 31, 2018 | Aug. 14, 2017 | Jun. 09, 2017 | |
NOTE PAYABLE (Details Narrative) | ||||||
Notes payable | $ 27,500 | $ 27,500 | $ 3,957 | $ 20,000 | $ 7,500 | |
Notes bear an interest rate | 57.00% | 40.00% | 40.00% | |||
Interest expense | 6,573 | $ 6,017 | ||||
Long-term notes payable | 3,957 | 3,957 | ||||
Accrued interest | $ 24,030 | $ 17,457 | ||||
Notes payable due date | Mar. 31, 2023 |
CONVERTIBLE NOTE PAYABLE (Detai
CONVERTIBLE NOTE PAYABLE (Details Narrative) - USD ($) | 6 Months Ended | 12 Months Ended | ||
Jun. 30, 2019 | Jun. 30, 2018 | Dec. 31, 2018 | Dec. 31, 2017 | |
Issuance of convertible note | $ 14,878 | $ 22,878 | ||
Interest expense | 4,829 | $ 6,078 | ||
Accrued interest | 17,118 | $ 12,290 | ||
Convertible Notes Payable Two [Member] | ||||
Issuance of convertible note | $ 11,200 | |||
Conversion price | $ 0.005 | |||
Interest rate per annum | 50.00% | |||
Beneficial conversion feature | $ 11,200 | |||
Debt amortized | 11,200 | |||
Convertible Notes Payable One [Member] | ||||
Issuance of convertible note | $ 6,803 | |||
Conversion price | $ 0.01 | |||
Interest rate per annum | 57.00% | |||
Beneficial conversion feature | $ 6,803 | |||
Debt amortized | 6,803 | |||
Convertible note | $ 4,000 | |||
Convertible note convferted into common stock | 400,000 | |||
Convertible Notes Payable [Member] | ||||
Issuance of convertible note | $ 4,875 | |||
Conversion price | $ 0.01 | |||
Interest rate per annum | 57.00% | |||
Beneficial conversion feature | $ 4,875 | |||
Debt amortized | $ 4,875 | |||
Convertible note | $ 4,000 | |||
Convertible note convferted into common stock | 400,000 |
EQUITY (Details Narrative)
EQUITY (Details Narrative) - USD ($) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2019 | Dec. 31, 2018 | |
Preferred stock, par value per share (in dollars per share) | $ 0.0001 | $ 0.0001 |
Preferred stock, shares authorized | 50,000,000 | 50,000,000 |
Preferred Stock, shares issued | 0 | 0 |
Preferred Stock, shares outstanding | 0 | 0 |
Common stock, par value per share (in dollars per share) | $ 0.0001 | $ 0.0001 |
Common stock, shares authorized | 100,000,000 | 100,000,000 |
Common stock, shares issued | 8,042,516 | 242,516 |
Common stock, shares outstanding | 8,042,516 | 242,516 |
Conversion of debt amount | $ 14,878 | $ 22,878 |
Chief Executive Officer [Member] | ||
Shares issued for compensation | 7,000,000 | |
Common stock Shares | ||
Conversion of debt shares | 800,000 | |
Conversion of debt amount | $ 8,000 |
RELATED TRANSACTIONS (Details N
RELATED TRANSACTIONS (Details Narrative) - USD ($) | 6 Months Ended | ||
Jun. 30, 2019 | Jun. 30, 2018 | Dec. 31, 2018 | |
Due to related parties | $ 128,785 | $ 100,172 | |
Loan from related parties | 28,613 | $ 28,669 | |
Directors [Member] | |||
Loan from related parties | $ 28,613 | $ 28,669 |
DISCONTINUED OPERATIONS (Detail
DISCONTINUED OPERATIONS (Details) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2019 | Jun. 30, 2018 | Jun. 30, 2019 | Jun. 30, 2018 | |
Professional | $ 10,090 | $ 18,519 | $ 28,715 | $ 20,007 |
Loss from discontinued operations, net of tax | (1,736) | (6,648) | ||
Discontinued Operations [Member] | ||||
Revenue | 2,183 | 4,470 | ||
Cost of goods | (1,644) | (6,398) | ||
Gross profit | 539 | (1,928) | ||
General and administration | 2,275 | 4,470 | ||
Professional | 250 | |||
Operating loss | (1,736) | (6,648) | ||
Income tax provision | ||||
Loss from discontinued operations, net of tax | $ (1,736) | $ (6,648) |